BacoCure is developing a novel bacterial product for local therapy (intravesicular) of patients with non-muscle invasive bladder cancer.

BacoCure's lead product is a novel mutated and inactivated uropathogenic bacteria that has demonstrated impressive anti-tumor effects via a novel and differentiated mechanism of action with a better safety profile compared to Bacillus Calmette-Guerin.

The product is at an advanced preclinical development stage.